Cytochroma announces appointment of Gordon Ngan, CFA, MBA as Executive Director, Corporate Development
Mr. Ngan brings to Cytochroma more than 10 years of finance, capitalmarkets, investor relations, and business development experience. Mostrecently, Mr. Ngan was Associate Analyst, Biotechnology and Pharmaceuticalsfor the Equity Research group at National Bank Financial where he was involvedin identifying and researching promising healthcare companies. Previous to hisexperiences on the sellside, he held a number of industry roles at BioChemPharma and Shire Pharmaceuticals Group plc, including Head of North AmericanInvestor Relations, and then Global Head of Investor Relations, followed by arole in business development at Shire's UK headquarters. In this latter role,Mr. Ngan worked on a number of successful partnership deals in the renal,hematology, and CNS fields.
"We are pleased to welcome Gordon to the management team at Cytochroma,"said Charles W. Bishop, PhD, President and CEO. "We intend to further developCytochroma's capital markets and investor strategy and Gordon brings valuableexperience and a unique perspective that will play a critical role inachieving this goal."
"Cytochroma has an experienced management team which has built aremarkable portfolio of renal products addressing clear areas of unmet medicalneed and has established strong relationships with key opinion leaders in thescientific and clinical community. I am delighted to join Cytochroma at thisexciting stage of the Company's development," stated Mr. Ngan. "I look forwardto working with investors and corporate partners to rapidly grow the companyand advance its products."
About Cytochroma Inc.
Cytochroma (www.cytochroma.com) is a specialty pharmaceutical companyengaged in the development and commercialization of proprietary products totreat and prevent the clinical consequences of Vitamin D insufficiency. TheCompany has an advanced portfolio of new therapies for Vitamin D insufficiencyand secondary hyperparathyroidism associated with CKD. In addition, theCompany is developing novel therapies to treat hyperproliferative disorders,such as cancer and psoriasis, and hyperphosphatemia.
SOURCE Cytochroma Inc.
You May Also Like